FIRST AMENDMENT TO THEDevelopment and Option Agreement • August 5th, 2020 • Harpoon Therapeutics, Inc. • Biological products, (no disgnostic substances)
This First Amendment (the “First Amendment”) to the Development and Option Agreement dated November 20, 2019 (the “Agreement”) by and between Harpoon Therapeutics, Inc., a Delaware corporation (“Harpoon”), and AbbVie Biotechnology Ltd, a Bermuda corporation (“AbbVie”) is made effective as of the date of the final signature to this First Amendment. Harpoon and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
ContractDevelopment and Option Agreement • August 5th, 2020 • Harpoon Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
